Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study
Background Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South...
Saved in:
| Published in | BMC infectious diseases Vol. 22; no. 1; pp. 384 - 10 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
17.04.2022
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2334 1471-2334 |
| DOI | 10.1186/s12879-022-07370-x |
Cover
| Abstract | Background
Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea.
Methods
We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients.
Results
The mean ± standard deviation of FLI were 25.01 ± 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11–2.82), P = 0.017) compared with the lowest tertile (T1).
Conclusions
Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. |
|---|---|
| AbstractList | Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea.BACKGROUNDResearch on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea.We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients.METHODSWe included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients.The mean ± standard deviation of FLI were 25.01 ± 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11-2.82), P = 0.017) compared with the lowest tertile (T1).RESULTSThe mean ± standard deviation of FLI were 25.01 ± 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11-2.82), P = 0.017) compared with the lowest tertile (T1).Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19.CONCLUSIONSOur study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. Abstract Background Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea. Methods We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients. Results The mean ± standard deviation of FLI were 25.01 ± 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11–2.82), P = 0.017) compared with the lowest tertile (T1). Conclusions Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients. The mean [+ or -] standard deviation of FLI were 25.01 [+ or -] 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11-2.82), P = 0.017) compared with the lowest tertile (T1). Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea. We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients. The mean ± standard deviation of FLI were 25.01 ± 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11-2.82), P = 0.017) compared with the lowest tertile (T1). Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. Background Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea. Methods We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients. Results The mean [+ or -] standard deviation of FLI were 25.01 [+ or -] 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11-2.82), P = 0.017) compared with the lowest tertile (T1). Conclusions Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. Keywords: COVID-19, Fatty liver index, Non-alcoholic fatty liver, Mechanical ventilation, Prognosis Background Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea. Methods We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients. Results The mean ± standard deviation of FLI were 25.01 ± 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11–2.82), P = 0.017) compared with the lowest tertile (T1). Conclusions Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. Background Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between the fatty liver index (FLI), a non-invasive and simple marker of NAFLD, and the severe complications of COVID-19 patients in South Korea. Methods We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated using triglyceride, body mass index, glutamyl transpeptidase, and waist circumference, which were obtained from the national health screening program data. Severe complications related to COVID-19 were defined as the composite of mechanical ventilation, intensive care unit treatment, high-oxygen flow therapy, and death within 2 months after a COVID-19 infection. We performed a multivariate logistic regression analysis for the development of severe complications in COVID-19 patients. Results The mean ± standard deviation of FLI were 25.01 ± 22.64. Severe complications from COVID-19 occurred in 223 (7.14%) patients, including mechanical ventilation in 82 (2.63%) patients, ICU admission in 126 (4.04%), high-flow oxygen therapy in 75 (2.40%), and death in 94 (3.01%) patients, respectively. The multivariate analysis indicated that the highest tertile (T3) of FLI was positively associated with severe complications from COVID-19 (adjusted odds ratio (OR): 1.77, 95% confidence interval (CI) (1.11–2.82), P = 0.017) compared with the lowest tertile (T1). Conclusions Our study demonstrated that FLI, which represents NAFLD, was positively associated with an increased risk of severe complications from COVID-19. FLI might be used as a prognostic marker for the severity of COVID-19. |
| ArticleNumber | 384 |
| Audience | Academic |
| Author | Jeon, Jimin Song, Tae-Jin Chang, Yoonkyung Kim, Jinkwon |
| Author_xml | – sequence: 1 givenname: Yoonkyung surname: Chang fullname: Chang, Yoonkyung organization: Department of Neurology, Mokdong Hospital, Ewha Woman’s University College of Medicine – sequence: 2 givenname: Jimin surname: Jeon fullname: Jeon, Jimin organization: Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine – sequence: 3 givenname: Tae-Jin orcidid: 0000-0002-9937-762X surname: Song fullname: Song, Tae-Jin email: knstar@ewha.ac.kr organization: Department of Neurology, Seoul Hospital, Ewha Woman’s University College of Medicine – sequence: 4 givenname: Jinkwon surname: Kim fullname: Kim, Jinkwon email: antithrombus@gmail.com organization: Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35430797$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk8lu2zAQhoUiRbO0L9BDQaCX9qCUm0SxhwJBuhkIYKBLrgRNjmymsuiIdOK8Qx-6Eztp4qAICh5EzHz_T3E4s1_s9LGHonjJ6CFjTf0uMd4oXVLOS6qEouXqSbHHpGIlF0Lu3NvvFvspnVHKVMP1s2JXVFJQpdVe8fsopeiCzSH2ZAL5EqAneQaktTlfkS5cwEBC72FFbO_XmSGkXyS2JAHmgLg4X3TBrR0SouR4fDr6WDJNFhiDPqf3xJJ-nb8MHvWQh5gW4DKao3wWh0xSXvqr58XT1nYJXtx8D4qfnz_9OP5anoy_jI6PTkpXqyqX2grtKyut59LRpgKvvBK1a2DSWlFhJcDWTlS2vmZ07aSSnFrW6omW0oI4KEYbXx_tmVkMYW6HKxNtMOtAHKbGDjm4DkzLNJ34VrO28rLW3jJaUwVSNkLaRlbo9WHjtVhO5uAdXniw3ZbpdqYPMzONF0ZTJiSXaPDmxmCI50tI2cxDctB1toe4TIbXFadc4wsj-voBehaXQ4-l2lCUMV7dUVOLFwh9G_Fcd21qjhTFZxeiUkgd_oPC5WEeHDZaGzC-JXi7JUAmwypP7TIlM_r-7f_Z8ek2--p-Af9W7rZHEWg2gMO2SQO0xoW8bif849AZRs31OJjNOBgcB7MeB7NCKX8gvXV_VCQ2ooRwP4XhrsqPqP4AiQgcLA |
| CitedBy_id | crossref_primary_10_62087_hpr_2024_0008 crossref_primary_10_3390_medicina60081325 crossref_primary_10_1111_liv_15815 crossref_primary_10_1016_j_imj_2023_04_002 crossref_primary_10_3390_vaccines10050799 crossref_primary_10_3390_medicina59010062 crossref_primary_10_1007_s13105_023_00991_z crossref_primary_10_5501_wjv_v12_i1_30 crossref_primary_10_3390_medicina59071239 crossref_primary_10_3748_wjg_v29_i2_367 crossref_primary_10_3390_v15051072 crossref_primary_10_3748_wjg_v29_i21_3362 crossref_primary_10_1080_08998280_2023_2231721 crossref_primary_10_1111_jns_12507 crossref_primary_10_3390_jcm13092687 crossref_primary_10_3390_vaccines11010089 |
| Cites_doi | 10.23876/j.krcp.18.0128 10.1001/jama.2020.12839 10.1186/s12933-019-0874-5 10.1016/j.metabol.2020.154244 10.1016/j.metabol.2015.09.017 10.1097/MD.0000000000004447 10.1016/j.febslet.2007.11.057 10.1136/bmj.m1198 10.3389/fendo.2021.638615 10.1136/bmj.m1091 10.1111/jgh.13814 10.1016/j.dsx.2021.03.019 10.1371/journal.pone.0247661 10.1007/s00125-020-05112-9 10.1111/jocs.15274 10.1016/j.jhep.2018.08.011 10.1002/JPER.20-0053 10.1016/S2215-0366(20)30421-1 10.1136/bmjopen-2017-016640 10.1016/j.diabet.2021.101252 10.2353/ajpath.2006.050875 10.1016/S2214-109X(20)30264-3 10.1371/journal.pone.0143560 10.7570/jomes.2018.27.1.46 10.1007/s11684-020-0754-0 10.1007/s10120-020-01085-1 10.1186/s12933-020-01025-4 10.1371/journal.pmed.1003564 10.1136/gutjnl-2020-322248 10.1016/S2213-2600(20)30076-X 10.2215/CJN.13820820 10.1186/s12872-020-01444-x 10.1016/j.cgh.2012.12.031 10.1161/CIRCULATIONAHA.105.169404 10.1371/journal.pone.0180951 10.1111/jcpe.13373 10.1016/j.jhep.2020.03.044 10.1186/1471-230X-6-33 10.1016/j.aohep.2020.09.015 10.1371/journal.pone.0094059 10.1016/j.jaip.2021.04.014 10.7555/JBR.31.20160153 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12879-022-07370-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals (Selected full-text) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2334 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_f190bdf91f5d469da10607e44834a845 PMC9013424 A700793357 35430797 10_1186_s12879_022_07370_x |
| Genre | Journal Article |
| GeographicLocations | South Korea |
| GeographicLocations_xml | – name: South Korea |
| GrantInformation_xml | – fundername: Ministry of Education grantid: 2021R1F1A1048113; 2020R1I1A1A01060447 funderid: http://dx.doi.org/10.13039/501100002701 – fundername: ministry of education grantid: 2021R1I1A1A01059868 – fundername: Ministry of Education grantid: 2020R1I1A1A01060447 – fundername: Ministry of Education grantid: 2021R1F1A1048113 – fundername: ; grantid: 2021R1I1A1A01059868 – fundername: ; grantid: 2021R1F1A1048113; 2020R1I1A1A01060447 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7QL 7T2 7U9 7XB 8FK AZQEC C1K COVID DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c675t-9a39d5a4ad24c085ed7d736c8ebfa35370ea6c35a6a4ad96c47420a1f9b944ae3 |
| IEDL.DBID | M48 |
| ISSN | 1471-2334 |
| IngestDate | Wed Aug 27 01:26:14 EDT 2025 Thu Aug 21 14:14:44 EDT 2025 Fri Sep 05 13:35:38 EDT 2025 Fri Jul 25 21:10:43 EDT 2025 Tue Jun 17 21:24:06 EDT 2025 Tue Jun 10 20:24:37 EDT 2025 Fri Jun 27 03:59:19 EDT 2025 Fri Jun 27 03:49:53 EDT 2025 Thu Apr 03 07:03:55 EDT 2025 Tue Jul 01 03:10:37 EDT 2025 Thu Apr 24 23:03:20 EDT 2025 Sat Sep 06 07:26:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 Fatty liver index Non-alcoholic fatty liver Prognosis Mechanical ventilation |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c675t-9a39d5a4ad24c085ed7d736c8ebfa35370ea6c35a6a4ad96c47420a1f9b944ae3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-9937-762X |
| OpenAccessLink | https://doi.org/10.1186/s12879-022-07370-x |
| PMID | 35430797 |
| PQID | 2652001125 |
| PQPubID | 42582 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f190bdf91f5d469da10607e44834a845 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9013424 proquest_miscellaneous_2652029073 proquest_journals_2652001125 gale_infotracmisc_A700793357 gale_infotracacademiconefile_A700793357 gale_incontextgauss_ISR_A700793357 gale_incontextgauss_IOV_A700793357 pubmed_primary_35430797 crossref_citationtrail_10_1186_s12879_022_07370_x crossref_primary_10_1186_s12879_022_07370_x springer_journals_10_1186_s12879_022_07370_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-17 |
| PublicationDateYYYYMMDD | 2022-04-17 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAbbrev | BMC Infect Dis |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | H Pakhchanian (7370_CR6) 2021; 16 TJ Song (7370_CR19) 2020; 47 I Lopez-Mendez (7370_CR40) 2021; 20 KI Zheng (7370_CR38) 2020; 108 P Metrakos (7370_CR8) 2018; 32 EM Koehler (7370_CR24) 2013; 11 WJ Wiersinga (7370_CR2) 2020; 324 Y Chang (7370_CR21) 2020; 63 JH Roh (7370_CR29) 2020; 20 JH Huh (7370_CR10) 2015; 10 VW Wong (7370_CR36) 2018; 69 L Sviklāne (7370_CR14) 2018; 33 D Ji (7370_CR37) 2020; 73 S Kahl (7370_CR15) 2014; 9 SW Lee (7370_CR17) 2020; 7 NK Polakos (7370_CR43) 2006; 168 SC Seong (7370_CR18) 2017; 7 KM Kim (7370_CR31) 2019; 38 M-H Woo (7370_CR25) 2019; 18 X Zou (7370_CR41) 2020; 14 JH Huh (7370_CR12) 2017; 12 H Lim (7370_CR32) 2021; 16 CH Lee (7370_CR22) 2021; 12 TK Oh (7370_CR27) 2021; 36 A Lonardo (7370_CR9) 2016; 65 TJ Song (7370_CR33) 2021; 47 C de Luca (7370_CR44) 2008; 582 A Singh (7370_CR39) 2021; 15 D Yadav (7370_CR11) 2016; 95 RE Jordan (7370_CR5) 2020; 368 SW Lee (7370_CR16) 2021; 70 M Reid (7370_CR1) 2021; 18 7370_CR3 Z Xu (7370_CR42) 2020; 8 T Chen (7370_CR4) 2020; 368 MH Seo (7370_CR28) 2018; 27 SM Grundy (7370_CR35) 2005; 112 J Kim (7370_CR26) 2020; 23 JH Kim (7370_CR30) 2021; 9 A Clark (7370_CR7) 2020; 8 G Bedogni (7370_CR13) 2006; 6 Y Chang (7370_CR20) 2021; 92 JH Kim (7370_CR23) 2020; 19 J Lee (7370_CR34) 2016; 46 |
| References_xml | – volume: 38 start-page: 382 year: 2019 ident: 7370_CR31 publication-title: Kidney Res Clin Pract doi: 10.23876/j.krcp.18.0128 – volume: 324 start-page: 782 year: 2020 ident: 7370_CR2 publication-title: JAMA doi: 10.1001/jama.2020.12839 – volume: 18 start-page: 67 year: 2019 ident: 7370_CR25 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-019-0874-5 – volume: 108 start-page: 154244 year: 2020 ident: 7370_CR38 publication-title: Metab Clin Exp doi: 10.1016/j.metabol.2020.154244 – volume: 65 start-page: 1136 year: 2016 ident: 7370_CR9 publication-title: Metabolism doi: 10.1016/j.metabol.2015.09.017 – volume: 95 start-page: e4447 year: 2016 ident: 7370_CR11 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000004447 – volume: 582 start-page: 97 year: 2008 ident: 7370_CR44 publication-title: FEBS Lett doi: 10.1016/j.febslet.2007.11.057 – volume: 368 start-page: m1198 year: 2020 ident: 7370_CR5 publication-title: BMJ doi: 10.1136/bmj.m1198 – volume: 12 start-page: 638615 year: 2021 ident: 7370_CR22 publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2021.638615 – ident: 7370_CR3 – volume: 368 start-page: m1091 year: 2020 ident: 7370_CR4 publication-title: BMJ doi: 10.1136/bmj.m1091 – volume: 33 start-page: 270 year: 2018 ident: 7370_CR14 publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13814 – volume: 15 start-page: 813 year: 2021 ident: 7370_CR39 publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2021.03.019 – volume: 16 start-page: e0247661 year: 2021 ident: 7370_CR32 publication-title: PLoS ONE doi: 10.1371/journal.pone.0247661 – volume: 63 start-page: 924 year: 2020 ident: 7370_CR21 publication-title: Diabetologia doi: 10.1007/s00125-020-05112-9 – volume: 36 start-page: 603 year: 2021 ident: 7370_CR27 publication-title: J Card Surg doi: 10.1111/jocs.15274 – volume: 69 start-page: 1349 year: 2018 ident: 7370_CR36 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.08.011 – volume: 92 start-page: 87 year: 2021 ident: 7370_CR20 publication-title: J Periodontol doi: 10.1002/JPER.20-0053 – volume: 7 start-page: 1025 year: 2020 ident: 7370_CR17 publication-title: Lancet Psychiatry doi: 10.1016/S2215-0366(20)30421-1 – volume: 7 start-page: e016640 year: 2017 ident: 7370_CR18 publication-title: BMJ Open doi: 10.1136/bmjopen-2017-016640 – volume: 47 start-page: 101252 year: 2021 ident: 7370_CR33 publication-title: Diabetes Metab doi: 10.1016/j.diabet.2021.101252 – volume: 168 start-page: 1169 year: 2006 ident: 7370_CR43 publication-title: Am J Pathol doi: 10.2353/ajpath.2006.050875 – volume: 8 start-page: e1003 year: 2020 ident: 7370_CR7 publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(20)30264-3 – volume: 10 start-page: e0143560 year: 2015 ident: 7370_CR10 publication-title: PLoS ONE doi: 10.1371/journal.pone.0143560 – volume: 27 start-page: 46 year: 2018 ident: 7370_CR28 publication-title: J Obes Metab Syndr doi: 10.7570/jomes.2018.27.1.46 – volume: 14 start-page: 185 year: 2020 ident: 7370_CR41 publication-title: Front Med doi: 10.1007/s11684-020-0754-0 – volume: 23 start-page: 1075 year: 2020 ident: 7370_CR26 publication-title: Gastric Cancer doi: 10.1007/s10120-020-01085-1 – volume: 19 start-page: 51 year: 2020 ident: 7370_CR23 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01025-4 – volume: 18 start-page: e1003564 year: 2021 ident: 7370_CR1 publication-title: PLoS Med doi: 10.1371/journal.pmed.1003564 – volume: 70 start-page: 76 year: 2021 ident: 7370_CR16 publication-title: Gut doi: 10.1136/gutjnl-2020-322248 – volume: 46 start-page: e15-e year: 2016 ident: 7370_CR34 publication-title: Int J Epidemiol – volume: 8 start-page: 420 year: 2020 ident: 7370_CR42 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30076-X – volume: 16 start-page: 785 year: 2021 ident: 7370_CR6 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.13820820 – volume: 20 start-page: 204 year: 2020 ident: 7370_CR29 publication-title: BMC Cardiovasc Disord doi: 10.1186/s12872-020-01444-x – volume: 11 start-page: 1201 year: 2013 ident: 7370_CR24 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2012.12.031 – volume: 112 start-page: 2735 year: 2005 ident: 7370_CR35 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.105.169404 – volume: 12 start-page: e0180951 year: 2017 ident: 7370_CR12 publication-title: PLoS ONE doi: 10.1371/journal.pone.0180951 – volume: 47 start-page: 1437 year: 2020 ident: 7370_CR19 publication-title: J Clin Periodontol doi: 10.1111/jcpe.13373 – volume: 73 start-page: 451 year: 2020 ident: 7370_CR37 publication-title: J Hepatol doi: 10.1016/j.jhep.2020.03.044 – volume: 6 start-page: 33 year: 2006 ident: 7370_CR13 publication-title: BMC Gastroenterol doi: 10.1186/1471-230X-6-33 – volume: 20 start-page: 100271 year: 2021 ident: 7370_CR40 publication-title: Ann Hepatol doi: 10.1016/j.aohep.2020.09.015 – volume: 9 start-page: e94059 year: 2014 ident: 7370_CR15 publication-title: PLoS ONE doi: 10.1371/journal.pone.0094059 – volume: 9 start-page: 2783 year: 2021 ident: 7370_CR30 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2021.04.014 – volume: 32 start-page: 327 year: 2018 ident: 7370_CR8 publication-title: J Biomed Res doi: 10.7555/JBR.31.20160153 |
| SSID | ssj0017829 |
| Score | 2.4166605 |
| Snippet | Background
Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the... Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the association between... We included 3122 COVID-19-positive patients from the nationwide COVID-19 cohort dataset in South Korea between January and June 2020. The FLI was calculated... Background Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the... Abstract Background Research on the association of non-alcoholic fatty liver disease (NAFLD) with prognosis in COVID-19 has been limited. We investigated the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 384 |
| SubjectTerms | Alcohol Analysis Asthma Blood pressure Body mass index Body size Cardiovascular disease Care and treatment Cholesterol Codes Cohort analysis Cohort Studies Confidence intervals Coronaviruses COVID-19 COVID-19 - complications COVID-19 - epidemiology Diabetes Diagnosis Family income Fatty liver Fatty liver index Health aspects Hepatitis Humans Hypertension Infections Infectious Diseases Insulin resistance Internal Medicine Kidney diseases Laboratories Liver Liver diseases Liver function tests Markers Measurement Mechanical ventilation Medical Microbiology Medical screening Medicine Medicine & Public Health Metabolism Methods Mortality Multivariate analysis Non-alcoholic fatty liver Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - epidemiology Oxygen Parasitology Patients Prognosis Questionnaires Regression analysis Retrospective Studies Risk Factors Statistical analysis Triglycerides Tropical Medicine Ventilation Ventilators Viral diseases γ-Glutamyltransferase |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gIIOQOIDVPJx4za30oRapVAJa9WbZsV0qVQnaZEX5D_3RnXGcZVNUuHBdf46yM-N5xOPPhLyBKANZaymZ4ZlhEPFhzTnHWWq4dgX4Qx7OVh18rvaO-KeT8mTlqi_sCRvogQfBbXiIWMZ6mfnSQilnNdQwqXAcP4LpGQ_spalMx2Iq7h9A3JPjEZlZtdGBFxaSYec6mLRI2cUkDAW2_j998kpQut4weW3XNASj3Xvkbswi6ebw9vfJLdc8ILcP4j75Q3K5InUaW7EopHrU677_Rc-xGYMGokSqGxtGsMectp5CpHRzRyet5gClW4fH-9sskzQysXYfqKbDp8SfZxbmu37ejuc2Kd67O-9pIK99RI52d75t7bF47wKroXzomdSFtKXm2ua8hpTMWWFFUdUzZ7wuSpCf01VdlLpCjKxqDvV1qjMvjeSo4sdkrWkb95RQyN9caipnTV5wL6SB9Mfnua6dRt6fNCHZqAZVR1JyvBvjXIXiZFapQXUKVKeC6tRFQt4t5_wYKDn-iv6I2l0ikU47_ABGpqKRqX8ZWUJeo20oJMxosCPnVC-6Tu0fHqtNkSLHYFGKm0Bfv0xAbyPIt_BHax1PQYC4kIhrglyfIGHZ19Ph0U5VdDudyitk0YIUGt741XIYZ2IrXePaRcTkEsSTkCeDWS-FU5QcfL6Eh4uJwU-kNx1pzr4HUnLIKwue84S8H5fG79e6WTvP_od2npM7eVjanGVinaz184V7Aalib14Gr3AFv5pjMg priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1dT9YwFG4UE-ON8ZshmmpMvNCGfbTb6o3BVwmYIIkK4a7p1g5JyAbb3oj_wR_tOV03GAZu19NlO99tT59DyBuIMpC1CskKHhUMIj7YnLWchQXXNgF_yN3dqt1v6fY-_3ooDv2GW-fLKkef6By1aUrcI9-IUwQIguxAfDw9Y9g1Ck9XfQuN2-ROBD4YDTNfTCUeEUQ_OV6UydONDnxxJhnWr4NiZyE7nwUjh9n_v2e-FJqulk1eOTt1IWnrAbnvc0m6OQj_Ibll60fk7q4_LX9M_l7iPfUFWRQSPlrpvv9DT7Akgzq4RKpr40aw0pw2FYV4aVtLZwXnQEoXewc7n1kkqcdj7T5QTYcNxd_HBubbvm3G25sUu--2PXUQtk_I_taXn4tt5rsvsBIWET2TOpFGaK5NzEtIzKzJTJakZW6LSicC-Gd1WiZCp0gj05LDKjvUUSULyVHQT8lK3dR2lVDI4mxYpNYUccKrTBaQBFVxrEurEf0nDEg0ikGVHpocO2ScKLdEyVM1iE6B6JQTnToPyLtpzukAzHEj9SeU7kSJoNruQdMeKW-jqoLkqDCVjCpheCqNhuVymFmO-6065yIgr1E3FMJm1FiXc6SXXad29g7UZhYi0mAisuuIfnyfEb31RFUDP1pqfxcC2IVwXDPK9RklGH85Hx71VHnn06kLUwnIq2kYZ2JBXW2bpaeJJbAnIM8GtZ6YkwgOnl_Cy7OZws-4Nx-pj385aHLILhMe84C8H03j4rOul87azX_xnNyLndFyFmXrZKVvl_YFpIJ98dLZ-z95klrn priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQkRAXxJtAQQYhcQCLPGxnza0sVC1SqQS06s1yYhsqVQnaZAX8B340M44TNoUicV2Po-w8PJ_jmc-EPIUsA6hVKFbxrGKQ8SHmnOMsrbhxBayHPPRWHbyXe0f83Yk4iTQ52AuzeX6fLeTLDtbPUjGsOQdnLFMGePGyyAqJQbiUy-nEADKdGpti_jpvlngCP_-fq_BGGjpfInnunDSkn93r5FrEjXRnMPQNcsk1N8mVg3gyfov83NAzjcVXFMAd9abvf9AzLL-ggRqRmsaGEawqp62nkBvdytFZcTmI0uXh8f4blikauVe7V9TQ4ePht1ML812_asdOTYo37a56Guhqb5Oj3beflnss3rTAatgw9EyZQllhuLE5rwGEOVvaspD1wlXeFAL054ysC2EkyihZc9hRpybzqlIcjXqHbDVt4-4RCojNpZV0tsoL7ktVAeDxeW5qZ5DpJ01INppB15GGHG_DONNhO7KQejCdBtPpYDr9PSHPpzlfBxKOf0q_RutOkkigHX4Av9IxHrUHIFRZrzIvLJfKGtgap6Xj-G3VLLhIyBP0DY0UGQ3W4Hw2667T-4fHeqdMkVWwEOVFQh8_zISeRSHfwh-tTex7AHUh9dZMcnsmCYFez4dHP9Vxoel0LpE3C0AzvPHjaRhnYvFc49p1lMkVqCchdwe3npRTCA6rvIKHlzOHn2lvPtKcfgk05IAkC57zhLwYQ-P3a11snfv_J_6AXM1DEHOWldtkq1-t3UOAgX31KMT_L_8dVLo priority: 102 providerName: Springer Nature |
| Title | Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study |
| URI | https://link.springer.com/article/10.1186/s12879-022-07370-x https://www.ncbi.nlm.nih.gov/pubmed/35430797 https://www.proquest.com/docview/2652001125 https://www.proquest.com/docview/2652029073 https://pubmed.ncbi.nlm.nih.gov/PMC9013424 https://doaj.org/article/f190bdf91f5d469da10607e44834a845 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfGJiFeEN8ERmUQEg9gSGLHrpEQWsumDakbKnSq9mI5iTMmVQmkqdj-B_5ozq7TLWNDvERKfI6S-_Dd2eefEXoJXgai1kSSlEUpAY8PNmcMI2HKtKEwHjK3t2q0z3cn7PM0ma6h9rgjz8D5lamdPU9qUs_env48-wgG_8EZfJ-_m8MYKySxdemgsCIkEFNugGfiNhkbsfNVBfCG0u02EhGJKWXtJpor39FxVA7P_-9R-4LbulxSeWld1bmrnTvoto8z8dZSMe6iNVPeQzdHfiX9Pvp9QS7YF2thCAZxoZvmDM9suQZ2UIpYl7lrsVXouCow-FJTG9wpRgdSPDw43PtEIok9Vuv8PdZ4Odn46ySH_qapq3ZnJ7Yn89YNdvC2D9BkZ_vbcJf4kxlIBglGQ6SmMk8003nMMgjaTC5yQXnWN2mhaQL8M5pnNNHc0kieMcjAQx0VMpXMKsFDtF5WpXmMMER4Jky5ydOYskLIFAKkIo51ZrRFBgoDFLViUJmHLbenZ8yUS1_6XC1Fp0B0yolOnQbo9arPjyVoxz-pB1a6K0oLuO0eVPWx8varCgic0ryQUZHkjMtcQyodCsPsXKzusyRAL6xuKAupUdqanWO9mM_V3sGh2hKhRSGkibiO6Ou4Q_TKExUV_Gim_T4JYJeF6upQbnYoYWDIus2tnqrWrlTMLc4WBNnwxc9XzbanLbYrTbXwNLEE9gTo0VKtV8yhCQOvIOHloqPwHe51W8qT7w62HCJPymIWoDetaZx_1vXSefI_PHuKbsXOdBmJxCZab-qFeQbBYpP20A0xFXDtD6Me2hhs738Zw92QD3tu-qXnRgi4jgdHfwCL52jV |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fT9UwFG8QE_XF-N8pajUaH2RhW7v21sQYvEi4woVEgfBWu61DErLh3W6A7-Bn8TN6TrddGAbeeL09XW57_rY953cIeQteBqLWWPkJDxMfPD7onLXcDxJuLAN7yF1t1XhTrO3wb3vx3hz529XCYFplZxOdoc7KFO_IlyKBAEEQHcSfj3772DUKX1e7FhqNWKzb02M4slWfRivA33dRtPp1e7jmt10F_BSC49pXhqksNtxkEU8h4LCZzCQT6cAmuWExk4E1ImWxEUijRMrh9BiYMFeJ4rgA-O4NcpMzJjCFbDCcpZSE4G1VV5gzEEsV2H6pfMyXB0WSgX_Sc36uR8D_nuCcK7yYpnnhrda5wNV75G4bu9LlRtjukzlbPCC3xu3r_EPy5xyvaZsARiHApLmp61N6iCkg1MEzUlNkbgQz22mZU_DPdmJpL8EdSOlwa3e04oeKtviv1UdqaHOBeXyQwXxbT8quWpRit99JTR1k7iOycy18eUzmi7KwTwmFqNEGibBZEjGeS5VA0JVHkUmtQbShwCNhxwadtlDo2JHjULsj0UDohnUaWKcd6_SJRz7M5hw1QCBXUn9B7s4oEcTb_VBO9nVrE3QOwViS5SrM44wLlRk4ngfScrzfNQMee-QNyoZGmI4C84D2zbSq9GhrVy_LAJENWSwvI_rxvUf0viXKS1hoatraC9guhP_qUS70KMHYpP3hTk51a-wqfaaaHnk9G8aZmMBX2HLa0kQKtscjTxqxnm0Oizl4GgUflz2B7-1ef6Q4-OWg0CGaZTziHlnsVOPsb13OnWdXr-IVub22Pd7QG6PN9efkTuQUmPuhXCDz9WRqX0AYWicvne5T8vO6jc0_9HeYyQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQK1VcEOUZKGAQEgeImofjrLmVLasu0BYBrXqznNgulaqk2mQF_Ad-NDOOEzaFInFdj6PsvCee-UzIc4gykLVmIixYXIQQ8cHmjGFhVDBlUvCHzM1W7R_wvSP27iQ7WZnid93u_ZFkN9OAKE1Vu32hbWfiE77dgFfNRYid6KCieRRCFrkOlUqEej3l0-EcAeKf6Edl_rpvFI4cav-fvnklOF1unLx0euqC0uwmueGzSbrTiX-TXDPVLbKx78_Lb5OfK9ynviWLQspHrWrbH_QcmzKoA0ykqtJuBXvNaW0pREyzMHTUcg6kdHp4PN8NY0E9ImvzmirafVL8dqZhv2kXdT-_SfH-3UVLHYjtHXI0e_tluhf6-xfCEsqINhQqFTpTTOmElZCaGZ3rPOXlxBRWpRnwzyheppniSCN4yaDOjlRsRSEYivouWavqytwnFPI4ExXc6CJJmc1FAWmQTRJVGoX4P1FA4l4MsvTg5HhHxrl0RcqEy050EkQnnejk94C8HPZcdNAc_6R-g9IdKBFW2_1QL06lt1JpIT0qtBWxzTTjQisomKPcMPziqiYsC8gz1A2JwBkVduacqmXTyPnhsdzJI8QaTLP8KqLPn0ZELzyRreGPlspPQwC7EJBrRLk1ogTzL8fLvZ5K734amXBE04JUGt746bCMO7GlrjL10tMkAtgTkHudWg_MSTMGvl_Aw_ORwo-4N16pzr46cHLIL1OWsIC86k3j92tdLZ0H_0f-hGx83J3JD_OD9w_J9cTZMwvjfIustYuleQR5Yls8dq7gFyL7X_g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+the+fatty+liver+index+and+the+risk+of+severe+complications+in+COVID-19+patients%3A+a+nationwide+retrospective+cohort+study&rft.jtitle=BMC+infectious+diseases&rft.au=Chang%2C+Yoonkyung&rft.au=Jeon%2C+Jimin&rft.au=Song%2C+Tae-Jin&rft.au=Kim%2C+Jinkwon&rft.date=2022-04-17&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-022-07370-x&rft.externalDBID=ISR&rft.externalDocID=A700793357 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |